Prosecution Insights
Prosecution Insights
19 pending office actions • 11 art units • 18 examiners • 0 of 19 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 4 (21%) |
| §112 only | 4 (21%) |
| Double-patenting only | 3 (16%) |
| Double-patenting + other | 2 (11%) |
| Multi-statute (no §101) | 4 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARCSISIN, ELLEN JEAN | 2 | 34.0% | +50.2% |
| CONSTANTINE, CHARLES Z | 1 | 59.0% | +48.8% |
| ROMERO, KRISTEN WANG | 1 | 70.7% | +30.0% |
| BAUER, BRIANNA LEE | 1 | — | — |
| HAM, JIEUN | 1 | 50.0% | +62.5% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| COFFA, SERGIO | 1 | 61.1% | +33.2% |
| JOHNSON, TIRONE DEREK | 1 | — | — |
| LU, CHENG | 1 | 53.7% | +66.2% |
| NATARAJAN, MEERA | 1 | 62.3% | +17.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011807 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PEDIATRIC PATIENTS | BERHANE, SELAM | 73d overdue |
| 17838115 | METHOD AND SYSTEM FOR IMPROVED MANAGEMENT OF GENETIC DISEASES | MINCHELLA, KAITLYN L | 59d overdue |
| 17924610 | CIRCULATING B CELL SUBPOPULATIONS IN INDOLENT B CELL LYMPHOMA | SEITZ, ANTHONY JOSEPH | 14d |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ROMERO, KRISTEN WANG | — |
| 18568011 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM) | ALDARONDO, DASIA ALI | — |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | COFFA, SERGIO | — |
| 18026698 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING C5-MEDIATED GLOMERULAR NEPHRITIS (GN), INCLUDING LUPUS NEPHRITIS (LN) AND/OR IGA NEPHROPATHY (IGAN) | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18219138 | ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS | NATARAJAN, MEERA | 38d overdue |
| 17923148 | METHOD OF USING EXTRACELLULAR VESICLES TO DETECT COMPLEMENT ACTIVATION, AND USES THEREOF TO ASSESS AND/OR MONITOR TREATMENT OF A COMPLEMENT-MEDIATED DISEASE | MARCSISIN, ELLEN JEAN | 26d |
| 18798163 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS | CONSTANTINE, CHARLES Z | — |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ROMERO, KRISTEN WANG | — |
| 18577912 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF MYASTHENIA GRAVIS | HAM, JIEUN | — |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | COFFA, SERGIO | — |
| 18272906 | METHODS OF TREATING COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY USING AN ANTI-C5 ANTIBODY | LU, CHENG | — |
| 17952897 | METHOD FOR MEASURING THE PROTEASE ACTIVITY OF C3 AND C5 CONVERTASE OF THE ALTERNATIVE COMPLEMENT PATHWAY | MARCSISIN, ELLEN JEAN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1677 | 2 |
| 1641 | 2 |
| 1658 | 1 |
| 1642 | 1 |
| 1643 | 1 |
| 1652 | 1 |
| 1629 | 1 |
| 1674 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18798163 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS | CONSTANTINE, CHARLES Z | — | DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ROMERO, KRISTEN WANG | — | §102§103Other | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18719261 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | BAUER, BRIANNA LEE | — | §112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18577912 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF MYASTHENIA GRAVIS | HAM, JIEUN | — | DP | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18568011 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM) | ALDARONDO, DASIA ALI | — | DP | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | COFFA, SERGIO | 1658 | §102§112 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18026698 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING C5-MEDIATED GLOMERULAR NEPHRITIS (GN), INCLUDING LUPUS NEPHRITIS (LN) AND/OR IGA NEPHROPATHY (IGAN) | JOHNSON, TIRONE DEREK | 1675 | §102§103 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18272906 | METHODS OF TREATING COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY USING AN ANTI-C5 ANTIBODY | LU, CHENG | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Jul 18, 2023 |
| 18219138 | ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS | NATARAJAN, MEERA | 1643 | §103 | Final Rejection | 38d overdue | Pending | Jul 07, 2023 |
| 18032973 | METHOD OF CONTROLLING TOTAL SIALIC ACID CONTENT (TSAC) DURING MANUFACTURING OF ALKALINE PHOSPHATASE | RAMIREZ, DELIA M | 1652 | §112DP | Final Rejection | — | Pending | Apr 20, 2023 |
| 18011807 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PEDIATRIC PATIENTS | BERHANE, SELAM | 1675 | §102§112Other | Non-Final OA | 73d overdue | Pending | Dec 20, 2022 |
| 17924610 | CIRCULATING B CELL SUBPOPULATIONS IN INDOLENT B CELL LYMPHOMA | SEITZ, ANTHONY JOSEPH | 1629 | §101§103§112Other | Non-Final OA | 14d | Pending | Nov 10, 2022 |
| 17923148 | METHOD OF USING EXTRACELLULAR VESICLES TO DETECT COMPLEMENT ACTIVATION, AND USES THEREOF TO ASSESS AND/OR MONITOR TREATMENT OF A COMPLEMENT-MEDIATED DISEASE | MARCSISIN, ELLEN JEAN | 1677 | §112 | Non-Final OA | 26d | Pending | Nov 03, 2022 |
| 17952897 | METHOD FOR MEASURING THE PROTEASE ACTIVITY OF C3 AND C5 CONVERTASE OF THE ALTERNATIVE COMPLEMENT PATHWAY | MARCSISIN, ELLEN JEAN | 1677 | §103 | Final Rejection | — | Pending | Sep 26, 2022 |
| 17849793 | ANTI-C5A ANTIBODIES | HOWARD, ZACHARY C | 1674 | §112Other | Non-Final OA | — | Pending | Jun 27, 2022 |
| 17838115 | METHOD AND SYSTEM FOR IMPROVED MANAGEMENT OF GENETIC DISEASES | MINCHELLA, KAITLYN L | 1685 | §101§103§112Other | Final Rejection | 59d overdue | Pending | Jun 10, 2022 |
| 17738131 | HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS | KIM, YUNSOO | 1641 | §112Other | Non-Final OA | 19d | Pending | May 06, 2022 |
| 17612368 | METHODS OF TREATING VITILIGO USING AN ANTI-C5 ANTIBODY | TAYLOR, LIA ELAN | 1641 | §103Other | Non-Final OA | — | Pending | Nov 18, 2021 |
| 17421511 | METHODS FOR PREPARING AMMONIUM TETRATHIOMOLYBDATE | SAWYER, JENNIFER C | 1691 | §103 | Non-Final OA | — | Pending | Jul 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial